Company Overview of Arbor Pharmaceuticals, LLC
Arbor Pharmaceuticals, LLC, a specialty pharmaceutical company, researches, develops, manufactures, and commercializes prescription products for cardiovascular, hospital, neuroscience, and pediatric markets. The company develops new chemical entities, as well as already approved molecules for new indications or in improved dosage forms. It offers nitroglycerin lingual sprays for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease; angiotensin II receptor blockers that help blood vessels relax so that blood flows through them freely; and isosorbide dinitrate/hydralazine HCL for the treatment of heart failure. The company also provides carmustine implants...
Six Concourse Parkway
Atlanta, GA 30328
Founded in 2006
Key Executives for Arbor Pharmaceuticals, LLC
Chief Executive Officer, President and Director
Chief Compliance Officer, Vice President and General Counsel
Head of Business Development
Vice President of Commercial Operations
Compensation as of Fiscal Year 2016.
Arbor Pharmaceuticals, LLC Key Developments
Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC Announce the Launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) Otic Solution
Aug 29 16
Laboratorios SALVAT S.A. and Arbor Pharmaceuticals, LLC jointly announce the launch of OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) otic solution, the first and only antibiotic and steroid combination ear drop available in sterile, preservative-free single-dose vials. OTOVEL® is owned by SALVAT, and Arbor will be the exclusive distributor of the product in the U.S. OTOVEL® (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 %) is indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients (aged 6 months and older) due to S. aureus, S. pneumoniae, H. influenzae, M. catarrhalis, and P. aeruginosa. Two phase 3 multicenter, randomized, double-blind, active-controlled, parallel group trials were conducted to assess the efficacy and safety of OTOVEL® compared to ciprofloxacin otic solution and to fluocinolone acetonide otic solution.
Arbor Pharmaceuticals, LLC Launches Cetylev
Jun 13 16
Arbor Pharmaceuticals, LLC announced the launch of Cetylev (acetylcysteine) effervescent tablets for oral solution, a new acetaminophen overdose antidote with a lemon-mint taste and smell. Cetylev prevents and reduces injury to the liver after acute and chronic toxic acetaminophen ingestion. The effervescent tablets are simply dropped into water which dissolve into a pleasant lemon-mint flavored and scented oral solution. Currently, acetylcysteine solution is available in vials intended for inhalation which pharmacists typically mix with a diet cola for ingestion orally; a practice intended to mask the reported “rotten-egg” smell and taste. Another acetylcysteine treatment comes in an intravenous formulation. Cetylev is now commercially available to hospitals and being promoted by Arbor’s national Hospital Specialty Sales Team.
Debiopharm International SA and Arbor Pharmaceuticals, LCC Announce Execution of Distribution Agreement
Jan 12 16
Debiopharm International SA and Arbor Pharmaceuticals, LCC jointly announced the execution of a distribution agreement for the commercialization and promotion of triptorelin 22.5 mg in the United States for central precocious puberty (CPP). Under the terms of the agreement, Arbor acquires exclusive commercial rights for triptorelin 22.5 mg in the U.S., for the CPP indication. The product will be exported from Debiopharm Research and Manufacturing SA to Arbor. Once approved, triptorelin 22.5 mg will be made available primarily to pediatricians and pediatric endocrinologists.
Similar Private Companies By Industry
Recent Private Companies Transactions